[關(guān)鍵詞]
[摘要]
鈣調(diào)磷酸酶抑制劑(CNI)是實體器官移植和造血干細胞移植術(shù)后的主要免疫抑制藥物。盡管CNI極大的改善了移植患者預后,但該類藥物引起的不良反應也經(jīng)常發(fā)生。CNI所致的疼痛綜合征(CIPS)是一種罕見的、嚴重的不良反應,其發(fā)生與鈣調(diào)磷酸酶生理功能的中斷有關(guān)?;颊叱1憩F(xiàn)為雙下肢疼痛,嚴重影響患者運動能力和生活質(zhì)量,因此,主要對CIPS的流行病學、臨床表現(xiàn)、實驗室檢查、影像學表現(xiàn)、診斷、發(fā)病機制及治療選擇進行綜述,以期為臨床提供參考。
[Key word]
[Abstract]
Calcineurin inhibitors (CNI) are the mainstay immunosuppressive drugs for solid organ transplantation and hematopoietic stem cell transplantation. Although CNI excellently improve patient outcomes, adverse effects are frequently encountered. Calcineurin inhibitor-induced pain syndrome (CIPS) is a rare and severe adverse effect of CNI, which appears to be due to the interruption of the physiologic function of calcineurin. Patients with CIPS diagnosis involve pain in the lower extremities. CIPS seriously affects the activities of daily living and life quality of the patients. Therefore, the epidemiology, clinical manifestation, laboratory examination, imaging manifestations, diagnosis, pathogenesis, and treatment choices are reviewed in this paper, in order to provide references for clinical practice.
[中圖分類號]
R977
[基金項目]
國家自然科學基金資助項目(81503127)